Monday, 20th June Advances in Neuroblastoma Research Congress 2016

• Complexes of N-MYC and MYC with Aurora-A: an inroad to targeting MYC function for neuroblastoma therapy - Martin Eilers

• The role of PRC2 in the early neuroblastoma tumorigenesis in MYCN-Tg mice - Shoma Tsubota
• Transforming primary neural crest cells to model neuroblastoma reveals a lineage sensitivity to BET inhibitors - Kevin Freeman

• Human pluripotent stem cell-based models of MYCN-amplified neuroblastoma - Miller Huang
• SOX11 acts as part of the MYCN regulatory protein complex implicated in neuroblastoma - Bieke Decaesteker
• Aberrant activation of SHP2 cooperates with MYCN in neuroblastoma pathogenesis  - Shizhen (Jane) Zhu
• The ALK-F1174L activating mutation mediates the upregulation of gene cluster located in the 15qD1 genomic region including the Myc locus in tumors derived from murine neural crest progenitor cells - Annick Mühlethaler-Mottet
• Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis - Isabelle Janoueix-Lerosey
• Reactivation of cAMP /PKA pathway is an early event that relieves EZH2-mediated epigenetic suppression in High-Risk Neuroblastoma(HR-NB) - Carol Thiele

• Whole exome sequencing of circulating free tumour DNA for study of spatial and temporal tumor heterogeneity: accumulation of new mutations at tumor progression of neuroblastoma - Mathieu Chicard
• Liquid biopsies reveal exosomal miRNA modulation in high-risk neuroblastoma patients after the induction therapy - Martina Morini
• Detection of copy number aberrations in cell free DNA from plasma of neuroblastoma patients using shallow massive parallel sequencing  - Katleen De Preter
• The transcriptomic landscape of bone marrow-derived disseminated tumor cells of high-risk neuroblastoma patients - Fikret Rifatbegovic
• A novel neuroblastoma metastatic mouse model identifies genes, pathways and drugs regulating metastasis - Alex BK Seong
• A native and immunocompetent in vivo model of chemorefractory, bone-marrow metastatic, “ultra-high risk” neuroblastoma. - Giuseppe Barone

“Efficacy and safety of ch14.18/CHO in neuroblastoma”

by Holger N. Lode, MD

Presenter:        Holger Lode, MD
                      Professor and Chair of Pediatrics
                      University Medicine Greifswald
                      Germany

• The prognostic and therapeutic relevance of TERT activation in neuroblastoma - Andrea Kraemer
• Telomere biology in neuroblastoma: focusing on alteration of TERT promoter lesion - Eiso Hiyama
• Constitutive activation of ATM kinase in neuroblastoma cell lines with the alternative lengthening of telomeres (ALT) phenotype induces resistance to DNA damaging agents - Balakrishna Koneru
• A unique mechanism for the continual proliferation of high-risk neuroblastoma cells - Rebecca Dagg
• Targeting a novel MYCN onco-factor, PA2G4, for the treatment of neuroblastoma - Jessica Koach
• Targeting tumor-promoting neuroblastoma microenvironment; Inhibition of tumor development and progression by therapy targeting mPGES-1 and prostaglandin E₂ expression in cancer associated fibroblasts - Per Kogner

• Targeting the LIN28B/let-7 axis by small molecules in neuroblastoma - Alessandro Quattrone
• A small molecule kinome inhibitor screen identifies the TGF-beta-activated kinase 1 (TAK1) as a target for combination therapy in MYC-driven neuroblastoma - Meredith Irwin
• Preclinical characterization of meta-[²¹¹At]astatobenzylguanidine ([²¹¹At]MABG) as an alpha particle emitting systemic targeted radiotherapeutic for neuroblastoma   - Vandana Batra
• A CD56 (NCAM1) targeting antibody-drug conjugate is potently effective in preclinical models of high-risk neuroblastoma - Robyn T Sussman
• GPC2 is a putative oncogene and candidate immunotherapeutic target in high-risk neuroblastoma - Kristopher R Bosse
• Phase I study of anti-G_D2 humanized 3F8 (hu3F8) monoclonal antibody (MAb) plus GM-CSF: High dosing and major responses in patients with resistant high-risk neuroblastoma (HR-NB) - Shakeel Modak

The study of epigenetic deregulation of cancer cells has moved to the forefront of cancer research as a result of the recent discovery that across all tumor entities roughly 20% of all mutations affect genes implicated in processes controlling methylation and chromatin modification. At the same time, an increasing number of novel epigenetic drugs are emerging and going through in vitro, pre-clinical and clinical testing. CRISPR/Cas technology has revolutionized controlled genome editing offering new exciting possibilities to investigate the complex epigenetic control of gene expression in cancer cells even down to the single cell level. In this workshop we bring together experts in this field explaining how new insights into the highly complex epigenetic regulatory processes can provide deeper understanding of tumor initiation, progression and therapy resistance and how genome editing can aid to further fuel this discovery process, ultimately providing us the tools and data to identify novel drug targets and therapeutic strategies to combat neuroblastoma.

• CRISPR/Cas9 based genome editing - Stanley Qi
• Putting genes under the microscope: an exploration of the human transcriptome - Tim Mercer
• Exploring the role of chromatin remodeling factors in neuroblastoma oncogenesis using genome-editing of mice neural crest progenitors - Kevin Freeman
• Defining epigenetic drug targets in neuroblastoma; structure is function - Jason Shohet
• Round Table Discussion - Frank Speleman

Much of the pre-clinical and clinical research on neuroblastoma is aimed at discovering more effective therapy for the majority of children who present with clinically advanced disease. Even successful current therapy for advanced neuroblastoma can lead to severe short and longterm side-effects, indicating the need for improved treatment strategies. Recent advances in organic chemistry and structure-aided design have seen a marked increase in the number of available targeted anticancer drugs, but the relative rarity of neuroblastoma may mean that novel trial designs are required to more rapidly incorporate pre-clinical advances into frontline protocols. This significant shift, coupled with more sophisticated methods of minimal residual disease monitoring, techniques for detailed analysis of tumor heterogeneity and ‘window therapy’ trial designs used to assess treatment efficacy in real-time, suggest that traditional single comparison phase 3 trial designs may no longer be suited to the problem of incorporating promising single agent or combination therapies into the treatment of newly diagnosed patients. The advent of precision or personalised oncologic medicine, aimed at better matching the treatment to the target holds the promise of improved cure rates and lower side-effect profiles. However, the relatively low number of genomic targets in neuroblastoma and the poor availability of novel agents for paediatric patients, means the field faces significant clinical research challenges in the future. We have asked the leaders of frontline international Phase 3 clinical trials for advanced neuroblastoma and early phase trialists to debate the following hypothesis: “That a conventional single comparison, randomised, Phase 3 trial design is no longer appropriate for newly diagnosed advanced neuroblastoma patients”.

• Introductory remarks - Glenn Marshall
• Pre-debate Voting - Glenn Marshall
• Ruth Ladenstein, Chair, SIOPEN-HR1; St. Anna Kinderkrebsforschung e.V. & Children's Cancer Research Institute Vienna, Austria  - Ruth Ladenstein
• Julie Park, Chair, COG Neuroblastoma Steering Committee; Seattle Childrens Hospital & University of Washington, Seattle, USA - Julie Park
• Angelika Eggert, Chair, German Neuroblastoma Trial Group; Charité Universitätsmedizin Berlin, Germany - Angelika Eggert
• David Ziegler, Co-Chair, NANT Phase I/II DFMO trial; Sydney Children’s Hospital, Sydney Australia - David Ziegler
• Questions from the floor - Glenn Marshall
• Post-debate voting - Glenn Marshall

• New, highly selective MRP1 inhibitors show promising preclinical activity in neuroblastoma - Christine Gana
• The MCM complex is a critical node in the miR-183 signaling network of MYCN-amplified neuroblastoma cells -Hedi Deubzer
• The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse - Lara Riehl
• Stathmin expression regulates miR-382/PTPN14 expression in neuroblastoma cells - Sela T Po'uha
• The MRN complex controls replication stress and allows proliferation and survival in MYCN amplified neuroblastoma - Giuseppe Giannini
• CAMKV is a candidate immunotherapeutic target in MYCN-amplified neuroblastoma. - Robyn T Sussman
• Proteomic analysis of high-risk neuroblastoma identifies nuclear distribution protein C as a marker of differentiation and prognosis - Amos HP Loh
• EZH2 is highly expressed in neuroblastoma and plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity. - Laurel T. Bate-Eya
• Circulating tumor DNA for disease monitoring in neuroblastoma - Godelieve Tytgat
• Aurora Kinase A inhibition sensitizes neuroblastoma to ¹³¹I -MIBG - W. Clay Gustafson
• Isolation of circulating tumor and associated cells by microfiltration in patients with neuroblastoma - Navin Pinto
• Survival tree analysis of an independent cohort reveals risk factors as proposed in the INRG system - Barbara Hero
• Survival and prognostic factors for children 12 to 18 months of age with stage 4 non-MYCN amplified neuroblastoma treated in the SIOPEN high-risk trial - Claudia Pasqualini
• Phase II study of the combination of bevacizumab plus irinotecan and temozolomide for relapsed or refractory neuroblastoma - Shakeel Modak
• Impact of age and MNA amplification (MNA) on long-term survival rates: accurate estimation and refined modeling using innovative statistical approaches.  A SIOPEN study from the high risk neuroblastoma trial HR-NBL1/SIOPEN. - Ulrike Pötschger
• Ex vivo drug screening as a strategy for personalised therapy in high-risk neuroblastoma - Alvin Kamili

• Impact of bone marrow-derived disseminated neuroblastoma cells on the identification of the relapse seeding clone - M. Reza Abbasi
• Analyzing risk factors for stem-cell collection failure in patients on the High-Risk Neuroblastoma 1 trial (HR-NBL1/SIOPEN) - Shifra Ash
• Quantification of bone marrow disease in high risk neuroblastoma patients by anti-GD2 immunocytochemistry – impact on survival. A SIOPEN High Risk Study. - Klaus Beiske
• Central imaging review in the SIOPEN high-risk neuroblastoma trial: preliminary data on central nervous system recurrences - Pablo Berlanga
• Characteristics and risk factors of 517 patients with first recurrence from stage 4 neuroblastoma over 18 months - Frank Berthold
• Detection of PHOX2B and TH mRNA by RTqPCR in peripheral blood stem cell harvests may identify children with stage 4 neuroblastoma that have an increased risk of an event post reinfusion: a SIOPEN study - Sue A Burchill
• Genome-wide analysis of liquid biopsies reveals a novel layer of tumor heterogeneity in neuroblastoma - Louis Chesler
• Detection of tumor ALK Status in neuroblastoma patients using peripheral blood - Valérie Combaret
• Amplification of CDK4 and MDM2 is associated with atypical clinical features in high risk neuroblastoma patients - Susanne Fransson
• A comparison of ¹²³I-mIBG planar imaging and SPECT/CT with ⁶⁸Ga-DOTATATE PET/CT for staging and response assessment of high-risk neuroblastoma - Mark N Gaze
• Development of a targeted sequencing panel for detection of subclonal mutations in neuroblastoma at diagnosis - Jo Lynne Harenza
• Survival tree analysis of an independent cohort reveals risk factors as proposed in the INRG system - Barbara Hero
• An 18-gene Myc activity signature predicts poor clinical outcome in multiple Myc-associated cancer types - MoonSun Jung
• Opsoclonus myoclonus syndrome in children with neuroblastoma - Denis Kachanov
• Prognostic and predictive significance of p53, MDM2 and miRNAs gene expression in patients with neuroblastoma. - Natalia M Khranovska
• Microarray CGH analysis of genomic imbalances in neuroblastoma FFPE specimens – pilot study. - Teofila Książek
• Clinical characteristics and risk factor of transplantation-associated microangiopathy (TAM) in high-tisk neuroblastoma undergoing autologous peripheral blood stem cell transplantation (auto-PBSCT) - Noritaka Miyazawa
• Survival and prognostic factors for children 12 to 18 months of age with stage 4 non-MYCN amplified neuroblastoma treated in the SIOPEN high-risk trial - Claudia Pasqualini
• Isolation of circulating tumor and associated cells by microfiltration in patients with neuroblastoma - Navin Pinto
• Impact of age and MNA amplification (MNA) on long-term survival rates: accurate estimation and refined modeling using innovative statistical approaches.  A SIOPEN study from the high tisk neuroblastoma trial HR-NBL1/SIOPEN. - Ulrike Pötschger
• Circulating tumor DNA for disease monitoring in neuroblastoma - Jalenka van Wijk
• A flow cytometry backbone panel as a first step in detection of circulating tumor cells in neuroblastoma - Jalenka van Wijk
• Aurora Kinase A inhibition sensitizes neuroblastoma to ¹³¹I -MIBG - W. Clay Gustafson
• Ex vivo drug screening as a strategy for personalised therapy in high-risk neuroblastoma - Alvin Kamili
• A novel histone deacetylase inhibitor OBP-801 induces apoptosis in neuroblastoma tumor cells - Daisuke Kaneda
• Serum C-circles as biomarker of Alternative Lengthening of Telomeres (ALT) in neuroblastoma - Loretta MS Lau
• Proteomic analysis of high-risk neuroblastoma identifies nuclear distribution protein C as a marker of differentiation and prognosis - Amos HP Loh
• Targeted drug delivery using nanoparticles (NPs) in neuroblastoma (NB) xenografts - Ferro Nguyen
• Bromodomain-inhibition as therapeutic option for MYCN-amplified neuroblastoma - Maike Nortmeyer
• The Connectivity Map bioinformatics platform identifies agents that reverse the chemotherapy resistance phenotype in neuroblastoma - Jed G Nuchtern
• A screening for natural products identifies a flavonol as a synergistic compound with 13-cis retinoic acid in neuroblastoma - Alessandro Quattrone
• CYP26-mediated metabolism of retinoids is a putative mechanism of treatment resistance in neuroblastoma - Nilay Shah
• Anti-tropomyosin agents enhance the antitumor effectiveness of microtubule inhibitors in preclinical models of neuroblastoma - Justine Stehn
• Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150, decreases tumor-initiating potential of neuroblastoma cells and increases their chemosensitivity - Carol J Thiele
• Targeting the MYCN oncogene in MYCN-amplified neuroblastoma with a novel PI polyamide DNA-alkylating drug conjugate - Hiroyuki Yoda
• Combined antitumor therapy with metronomic administration of  topotecan and hypoxia-activated prodrug, evofosfamide, in neuroblastoma preclinical models - Libo Zhang
• EZH2 is highly expressed in neuroblastoma and plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity. - Laurel T. Bate-Eya
• The MCM complex is a critical node in the miR-183 signaling network of MYCN-amplified neuroblastoma cells - Hedi Deubzer
• A genome-wide MYCN synthetic lethal screen identifies inhibition of PRC2 as drug target in MYCN-amplified neuroblastoma cells - Moritz Gartlgruber
• Epigenetic silencing of CHD5 expression by histone modification in human neuroblastoma - Venkatadri Kolla
• R2: A public user-friendly website for integrated analysis of genomic data and associated clinical parameters in neuroblastoma - Jan Koster
• Non-random pattern of whole chromosome gains and losses in neuroblastoma with numerical chromosomal aberrations. - Tim Lammens
• Role of MiRNAs in the epigenetic silencing of CHD5, a tumor suppressor in neuroblastoma (NB) - Koumudi Naraparaju
• Clinical relevance of genomic and epigenomic classification of MYCN-non-amplified neuroblastoma - Miki Ohira
• Genomic characterization of high-risk neuroblastoma in Japan: A retrospective study of 537 cases by using updated follow-up data based on INRG variables  [Japan Neuroblastoma Study Group (JNBSG)] - Miki Ohira
• MicroRNA-204 suppresses neuroblastoma tumour growth through down-regulation of MYCN oncogene - Chi Yan Ooi
• Exploring m6A mRNA methylation for novel therapeutic chances in neuroblastoma - Alessandro Quattrone
• The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse - Lara Riehl
• CPEB1 down-regulated the expression of MYCN via tumor-suppressor miRNA let-7 in human neuroblastoma cells - Ya-Hui Tsai
• Genetic characteristics of 494 neuroblastomas using genome-wide analysis combined with immunohistochemistry - Kumiko Uryu
• End of life care for children with neuroblastoma: a retrospective study from the Royal Children Hospital Brisbane - David Cantelmi
• Physeal arrest leading to angular deformity after therapy with isotretinoin for high risk neuroblastoma (HR-NBL) - Angela Cha
• A multidisciplinary team care improved outcomes for children with high-risk neuroblastoma - Hsiu-Hao Chang
• The requirement for accurate standardization and methodology of dosimetry in international trials incorporating molecular radiotherapy (MRT) in the treatment of high-risk neuroblastoma - Matthew D Aldridge
• Antibodies specific for O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. - Stephane Birkle
• Importance of quality assurance in radiotherapy for optimal local control. A report from the SIOPEN radiotherapy committee of the High Risk Neuroblastoma Trial (HR-NBL1/SIOPEN) - Tom Boterberg
• Stromal collagen type XI alpha 1 COL11A1 expression in neuroblastoma - Bao C Bui
• Dinutuximab combined with chemotherapy in patients with multiply relapsed/refractory high risk neuroblastoma (HR-NBL) - Angela Cha
• Evaluation of genetic modified anaerobic Salmonella typhimurium as therapy for neuroblastoma: Comparison of response of orthotopic mouse models with different immunological backgrounds - Godfrey CF Chan
• Preclinical studies of anti-PDL-1/PD-1-based combination immunotherapy for Neuroblastoma - Maria V Corrias
• Which miRNAs should be developed into novel therapeutics for neuroblastoma? - Eoin Dodson
• Generation and characterization of a new chimeric human/mouse anti-idiotype antibody ganglidiximab for active immunotherapy against neuroblastoma - Christin Eger
• Role of Surgery in Patients older than 18 months with localized Neuroblastoma (Stage 1-3) - Barbara Hero
• More is less: radiation exposure to family caregivers and health care providers of paediatric neuroblastoma patients receiving ¹³¹I-MIBG therapy in Canada - Meredith Irwin
• Anti-GD2 antibody combined with activated natural killer cells leads to improved survival and decreased metastasis in a minimal residual disease mouse model of neuroblastoma - Eugene S Kim
• TLR3-Mediated innate immune response in the treatment of neuroblastoma - Li-Ling Lin
• Interleukin-2 adds toxicity to long term infusion treatment regimen of ch14.18/CHO antibody without measurable additional activity in relapsed/refractory neuroblastoma patients. - Holger Lode
• Galactose-α-1,3-galactose (a-Gal) glycosylation determinant on ch14.18 antibodies produced by CHO- or SP2/0 cell lines – potential clinical impact - Hans Loibner
• Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model - Suzanne P MacFarland
• Impact of radiotherapy and curie score on bone relapse in high-risk neuroblastoma - Kimikazu Matsumoto
• Phase II study of the combination of bevacizumab plus irinotecan and temozolomide for relapsed or refractory neuroblastoma - Shakeel Modak
• Event-free survival (EFS) and overall survival (OS) of MYCN-amplified stage 2/3 neuroblastoma with or without autologous stem-cell transplantation (ASCT) - Shakeel Modak
• The iTHER (individualized THERapy) program; personalized cancer treatment for relapsed pediatric cancer - Jan Molenaar
• The BEACON-Neuroblastoma ITCC/SIOPEN phase 2 trial for children with relapsed and refractory neuroblastoma: a progress report - Lucas Moreno
• Viability Of cryopreserved peripheral blood stem cells (PBSC) does not cuarantee functional activity: important implications for quality assurance of stem cell transplant programmes - Daniel A Morgenstern
• CAMKV is a candidate immunotherapeutic target in MYCN-amplified neuroblastoma. - Robyn T Sussman
• Significantly reduced relapse rate after KIR ligand incompatible allogeneic cord blood transplantation with nonmyeloablative conditioning for primary stage IV neuroblastoma - Yoshiyuki Takahashi
• Validation of a test-dose strategy prior intravenous melphalan in children with renal failure undergoing high-dose chemotherapy with autologous stem cell transplantation - Domonique Valteau-Couanet
• Dextran-Catechin conjugate targets copper metabolism in neuroblastoma - Orazio Vittorio
• Development of a novel transgenic neuroblastoma tumor model using genome editing - Saurabh Agarwal
• IGF2BP1 harbours prognostic significance by gene gain, diverse expression and interplay with MYCN   - Jessica L Bell
• Aldehyde dehydrogenases activity plays a key role in NB aggressive behavior - Annick Mühlethaler-Mottet
• Rab6B mediates the progression of neuroblastoma through the interaction with MTMR5 - Noriyuki Nishimura
• Characterization of patient-derived xenograft neuroblastoma cells - Camilla Persson
• Differentiation of Neuroblastoma is controlled by cdk-mediated regulation of the master regulator transcription factor Ascl1. - Anna Philpott
• MYCN-regulated nuclear hormone receptors impact differentiation and survival in neuroblastoma patients - Diogo Ribeiro
• CDX1 regulates cancer stemness pathway in neuroblastoma - Hisanori Takenobu
• BMCC1, a tumor suppressor protein that facilitates DNA-damage response and apoptosis, is associated with favorable prognosis of neuroblastoma - Yasutoshi Tatsumi
• DENN domain protein DENND2A regulates the progression of neuroblastoma - Nobuyuki Yamamoto
• Transmembrane adaptor protein PAG1 is a novel tumor suppressor in neuroblastoma - Saurabh Agarwal
• The identification of hypoxia regulated genes that confer a poor prognosis in neuroblastoma patients - Mark A Applebaum
• THe MAD Family members, MXI1 and MXI0, display distinct subcellular localization patterns in neuroblastoma - Michael B Armstrong
• The expression of Mxi1 and Mxi0 lead to differential effects on neuroblastoma pathogenesis and chemosensitivity. - Michael B Armstrong
• Targeting MYCN-amplified neuroblastoma through RORα activation. - Eveline Barbieri
• Identification of a novel protein that suppresses the ability of NDPK-A to promote the invasiveness of neuroblastoma cells - Christina L. Chang
• Reduced endoplasmic reticulum (ER)-mitochondria tethering as a cause of multidrug resistance in neuroblastoma - Jorida Coku
• An embryonic stem cell activated FOXM1 transcriptional program marks ultra-high-risk primary neuroblastoma patients for FDI-6 small molecule inhibition - Katleen De Preter
• Molecular control of neuroblastoma stem cell metabolism - Han-Fei Ding
• New, highly selective MRP1 inhibitors show promising preclinical activity in neuroblastoma - Christine Gana
• The MRN complex controls replication stress and allows proliferation and survival in MYCN amplified neuroblastoma - Giuseppe Giannini
• TRPM7 promotes Neuroblastoma progression - Dana-Lynn Koomoa
• Curcumin mediated apoptosis in human neuroblastoma cells via ROS and inhibition of sphingomyelin synthase and glycosylceramide synthase - Jacqueline M Kraveka
• PPP3CB is a novel prognostic indicator of high-risk neuroblastoma contributing to aggressive behaviors - Yuanyuan Li
• Clinical significance of a seven-gene hypoxia signature in neuroblastoma - Martina Morini
• The CXCR4/CXCR7/CXCL12 axis is involved in a secondary but complex control of neuroblastoma metastatic cell homing - Annick Mühlethaler-Mottet
• Stathmin expression regulates miR-382/PTPN14 expression in neuroblastoma cells - Sela T Po'uha
• Functional Genomics identifies novel therapeutic targets for retinoic acid combinations - Rachele Rosati
• A multidisciplinary approach to antigen discovery and immune profiling of Opsoclonus-Myoclonus Ataxia Syndrome associated with Neuroblastoma - Miriam Rosenberg
• Composite Neuroblastoma: Unique tumours with morphologically and genetically defined intratumoral heterogeneity - Hervé Sartelet
• The histone H3 lysine 4 presenter WDR5 is a potential therapeutic target in N-Myc-induced neuroblastoma. - Yuting Sun
• The signaling complex of tyrosine phosphatase SHP2 and docking protein ShcC regulates oncogenicity of neuroblastoma cells in a tyrosine-phosphorylation dependent manner. - Arata Tomiyama
• The role of p75^NTR during neuronal differentiation of neuroblastoma cells - Catarina Trager